Project Grant R43HL142396

This $181,772 project grant from the National Heart, Lung and Blood Institute will support research into coagulopathy in sepsis patients. The grantee, Beth Israel Deaconess Medical Center, will conduct an ancillary study using viscoelastic monitoring to examine the effects of randomly assigned fluid resuscitation strategies on coagulation parameters in sepsis patients. Specifically, the study aims to: 1) analyze how liberal versus restrictive fluid administration impacts coagulation measurements...

Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Children's Hospital Corporation (Boston Children's Hospital) a Project Grant totaling $489,500 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 25, 2025, with a completion date of June 30, 2027. This research initiative focuses on characterizing the biological role of αDβ2 as a novel complement receptor in acute lung injury associated with sepsis. The project will...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $473,937 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 25, 2025, for a project period extending through June 30, 2027. The award supports development of a novel point-of-care liquid biopsy diagnostic tool for early detection of sepsis-associated organ damage. The project leverages the institution's pioneering liquid biopsy...

This Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $412,250.00 to Arizona State University (ASU) to develop a real-time, automated smart catheter analyzer that can detect sepsis through continuous monitoring of urine biomarkers. The goal is to enable earlier diagnosis of sepsis, a life-threatening condition, within minutes rather than hours. This would allow clinicians to quickly intervene and support heart and lung...

Federal Project Grant Award Summary Aptus Biosciences LLC received a $356,500 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded on September 15, 2025, with a completion date of September 14, 2026. The award supports the development of chemically modified deoxyribonucleic acid (DNA) aptamers for rapid and accurate sepsis diagnosis. This research addresses a critical clinical gap: current...

This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...

Federal Project Grant Award Summary Baylor College of Medicine received a $181,440 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective February 1, 2026 through January 31, 2031. The grant funds a five-year research initiative investigating the role of interleukin-1 beta (IL-1B) and fibrin(ogen) interaction in sepsis-induced coagulopathy (SIC), a condition affecting up to 60% of...

SNJ Pharma Inc. received a $499,882 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) on September 15, 2025, with a completion date of August 31, 2026. The award funds research and development of a novel thrombolytic therapeutic agent designed to address pulmonary embolism (PE), a leading preventable cause of death among hospitalized patients. The company is advancing a recombinant form of...

Federal Project Grant Award Summary Emory University received a $110,635 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 12, 2025, through August 31, 2027. The research initiative, titled "The Role of Rheology and Transfusion on Microvascular Thrombosis in Sepsis," investigates the mechanisms underlying sepsis-related organ failure and mortality by examining how...